<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01056471</url>
  </required_header>
  <id_info>
    <org_study_id>CMM/EM/2008</org_study_id>
    <nct_id>NCT01056471</nct_id>
  </id_info>
  <brief_title>Autologous Mesenchymal Stem Cells From Adipose Tissue in Patients With Secondary Progressive Multiple Sclerosis</brief_title>
  <official_title>Multicenter Clinical Trial Phase I / II Randomized, Placebo-controlled Study to Evaluate Safety and Feasibility of Therapy With Two Different Doses of Autologous Mesenchymal Stem Cells in Patients With Secondary Progressive Multiple Sclerosis Who do Not Respond to Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Carlos III Health Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the safety and feasibility of regenerative
      therapy with mesenchymal stem cells from adipose tissue, administered intravenously in
      patients with secondary progressive multiple sclerosis who do not respond to treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate safety and tolerability related to the intravenous infusion of autologous mesenchymal stem cells</measure>
    <time_frame>12 months.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate effects on MS disease activity measured by: clinical variables, imaging variables, immunological and neurophysiologic analysis, neuropsychological and quality of life scales.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Autoimmune Diseases</condition>
  <condition>Immune System Diseases</condition>
  <condition>Demyelinating Diseases</condition>
  <condition>Nervous System Diseases</condition>
  <condition>Demyelinating Autoimmune Diseases, CNS</condition>
  <condition>Autoimmune Diseases of the Nervous System</condition>
  <arm_group>
    <arm_group_label>Low dose autologous mesenchymal cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose of infused cells is 10e6 cells/Kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose of infused cells is 4*10e6 cells/Kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Autologous mesenchymal stem cells from adipose tissue.</intervention_name>
    <description>Intravenous infusion of autologous mesenchymal stem cells.Dose:4*10e6 cells/Kg.</description>
    <arm_group_label>High dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Autologous mesenchymal stem cells from adipose tissue.</intervention_name>
    <description>Intravenous infusion of autologous mesenchymal stem cells. Dose: 10e6 cells/Kg.</description>
    <arm_group_label>Low dose autologous mesenchymal cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients diagnosed with Multiple Sclerosis (Poser and McDonald criteria).

          2. Secondary progressive MS patients with EDSS ≥ 5.5 and ≤ 9.

          3. Patients with treatment failure defined by: no response to immunomodulators /
             immunosuppressants, and showing activity in the form of 1 relapse in the last year or
             0.5 points in EDSS progression.

          4. Patients with no MS relapse and no steroid treatment within the month prior to
             inclusion.

          5. Patients who give written consent to participate in the study. -

        Exclusion Criteria:

          1. History of current pathology or current laboratory results indicative of any severe
             disease.

          2. Pacemaker or metallic implants that prevent MR imaging.

          3. Inability to complete questionnaires.

          4. Refusal to give informed consent.

          5. Predicted impossibility for a biopsy of at least 30 grams of fat tissue.

          6. Positive screening test for HIV, Hepatitis B or Hepatitis C.

          7. History of malignancy.

          8. Having been in treatment with any investigational drug or have undergone any
             experimental procedure in the 3 months prior to baseline.

          9. Body mass index&gt; 40 kg/m2.

         10. Patients who have been treated with prohibited concomitant medication during the month
             prior to inclusion in the study.

         11. Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oscar Fernandez Fernandez, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Regional Universitario Carlos Haya, Málaga, Spain.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guillermo Izquierdo Ayuso, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Virgen Macarena, Sevilla, Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Regional Universitario de Málaga</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.cabimer.es</url>
    <description>Andalusian Molecular Biology and Regenerative Medicine Centre</description>
  </link>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2010</study_first_submitted>
  <study_first_submitted_qc>January 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2010</study_first_posted>
  <last_update_submitted>August 4, 2015</last_update_submitted>
  <last_update_submitted_qc>August 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Mesenchymal Stem Cells</keyword>
  <keyword>Autologous</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
    <mesh_term>Immune System Diseases</mesh_term>
    <mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
    <mesh_term>Demyelinating Diseases</mesh_term>
    <mesh_term>Autoimmune Diseases of the Nervous System</mesh_term>
    <mesh_term>Demyelinating Autoimmune Diseases, CNS</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

